Back to Terpenology
Terpenology Cannabinoids · Conditions
Cannabinoid Monograph No. 05Medical Cannabis

Cannabinoid · C₁₉H₂₆O₂

THCV

Tetrahydrocannabivarin

Intoxicating only at higher doses · interesting metabolism signals, heavily oversold

The THCV molecule · drag to rotate
Full name
Tetrahydrocannabivarin
Formula
C₁₉H₂₆O₂
Molar mass
286.41 g/mol
Intoxicating
Only at higher doses
PubChem
CID 93147

THCV is the cannabinoid marketed as "diet weed," and that nickname is where the honesty has to start. Its appetite and weight effects come from mice; the one human trial that measured them found nothing. It is also not simply non-intoxicating, its effect flips with dose. A genuinely interesting molecule that is easy to oversell.

Where it stands legally

None.

Where the evidence stands

Ranked by how much each finding can actually tell you, strongest first. A trial in people outranks a study in cells, including when the answer is no.

Human trial

Modestly lowered fasting blood glucose in type-2 diabetes (pilot)

THCV (5 mg twice daily, 13 weeks) lowered fasting glucose and improved β-cell markers vs placebo. But it MISSED its primary endpoint (HDL), the THCV arm was tiny (~11–13 people), it has never been replicated, and it found NO effect on appetite or body weight. Non-psychoactive at this dose. Jadoon KA, Ratcliffe SH, Barrett DA, et al. (2016). Diabetes Care, 39:1777–1786. PubMed 27573936

Human trial  ·  not established

"Diet weed": suppresses appetite and causes weight loss

The appetite/weight effect is from mouse studies. The single human trial measured appetite and body weight and found NO significant THCV effect on either.

Animal studies

Improved insulin sensitivity in obese mice, without weight loss

The mechanistic basis for the diabetes pilot. Notably the metabolic benefit came WITHOUT reducing food intake or body weight in these mice. Wargent ET, Zaibi MS, Silvestri C, et al. (2013). Nutrition & Diabetes, 3:e68. PubMed 23712280

Animal studies

Acts differently at low vs high dose (not simply "non-psychoactive")

THCV blocks CB1 at low doses (so it is non-intoxicating there, and can even blunt THC) but can act as a CB1 agonist at higher doses. "Always non-psychoactive" is an overstatement. It is dose-dependent, and no human intoxication threshold has been defined. Pertwee RG, Thomas A, Stevenson LA, et al. (2007). British Journal of Pharmacology, 150:586–594. PubMed 17245367

Animal studies  ·  not established

Treats epilepsy or Parkinson’s in people

Anticonvulsant and Parkinson’s findings are rodent-only. Unlike CBD for epilepsy, THCV has zero human clinical data here.

No published study  ·  still open

A proven treatment for diabetes

One small pilot that missed its primary endpoint and was never replicated. Hypothesis-generating, not established.

No published study  ·  still open

Completely non-psychoactive

True only at low doses; its CB1 effect flips with dose in animals, and no human threshold is defined.

Chemical identity, formula and molar mass: PubChem CID 93147, National Center for Biotechnology Information.

Terpenology is educational, not medical advice. Cannabinoid effects are tendencies reported by patients and early research, never guaranteed outcomes. Work with your certifying physician and pharmacist.

Terpenology
Medicate Smarter, Not Harder™